Skip to main content

Articles

FDA Approvals, In the News
First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL
Read More
ASCO 2019 - Chronic Lymphocytic Leukemia
Effect of Fixed-Duration Venetoclax plus Obinutuzumab on Progression-Free Survival and Minimal Residual Disease Status in Treatment-Naïve Patients with CLL and Comorbidities
Read More
ASCO 2019 - Chronic Lymphocytic Leukemia
Three-Year Follow-Up of Acalabrutinib and Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL
Read More
ASCO 2019 - Chronic Lymphocytic Leukemia
Comparison of 3 Rituximab-Containing Regimens as Primary Therapy in Patients with WM
Read More
ASCO 2019 - Chronic Lymphocytic Leukemia
Patient-Reported Outcomes with Ibrutinib-Rituximab in WM: Results from iNNOVATE
Read More
ASCO 2019 - Chronic Lymphocytic Leukemia
Evaluation of MRD with Lisocabtagene Maraleucel, a CD19-Directed CAR T Therapy, in Patients with Relapsed/Refractory CLL/SLL
Read More
ASCO 2019 - Chronic Lymphocytic Leukemia
Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL
Read More
ASCO 2019 - Chronic Lymphocytic Leukemia
Evaluation of the PI3Kδ Inhibitor ME-401 in Patients with Relapsed/Refractory Follicular Lymphoma
Read More
ASCO 2019 - Chronic Lymphocytic Leukemia
Smart Start: Final Results of Rituximab, Lenalidomide, and Ibrutinib Lead-In Therapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Read More
ASCO 2019 - Chronic Lymphocytic Leukemia
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory CLL
Read More
Page 51 of 244
Results 501 - 510 of 2434